{Reference Type}: Journal Article
{Title}: In silico study suggests potential drugs that target CD151 to treat breast cancer and lioblastoma.
{Author}: Ramírez-Salinas G;Rosales-Hernandéz MC;Correa-Basurto J;Guerrero-González I;Hernández-Castro SS;Martinez-Archundia M;
{Journal}: J Comput Chem
{Volume}: 0
{Issue}: 0
{Year}: 2024 Jul 31
{Factor}: 3.672
{DOI}: 10.1002/jcc.27439
{Abstract}: Recently tetraspanin CD151 has been identified as an important biological target involved in metastatic processes which include cell adhesion, tumor progression processes, and so forth in different types of cancers, such as breast cancer and glioblastoma. This in Silico study considered 1603 compounds from the Food and Drug Administration database, after performing an ADMET analysis; we selected 853 ligands, which were used for docking analysis. The most promising ligands were selected from docking studies, based on two criteria: (a) showed lowest affinity to the CD151 protein and (b) they interact with the QRD motif, located in the second extracellular loop. Furthermore, we investigate the stability of the protein-ligand complexes through MD simulations as well as free energy MM-PBSA calculations. From these results, loperamide and glipizide were identified as the best evaluated drugs. We suggest an in vitro analysis is needed to confirm our in silico prediction studies.